Laboratories Thea

Ost-developpment

Laboratoires Thea S.a.

Jacques Luyckx

Michel Faurie

Alain Defemme

Jean-Pierre Lontrade

Henri Chibret

Frederic Pilotaz

Pablo Goldschmidt

Thierry Coquel

Robert Boniface

The invention relates to a pharmaceutical composition for preventing and/or treating eye infections, which is to be used by local application. It is in particular directed towards such a composition which is in the form of an eye lotion which can be distributed by drops, in which an antibiotic of the macrolide class, such as azithromycin, is in solution in an oily vehicle. This vehicle is, in particular, of the type of product essentially consisting of medium-chain triglycerides in which the alcohol functions of the glycerol are entirely esterified by carboxylic acids made from saturated hydrocarbons, the molecule of which comprises from 5 to 12 carbon atoms. They are preferably linear-chain fatty acids comprising from 8 to 10 carbon atoms, such as caprylic acid or capric acid. The composition is advantageously prepared by dissolving the active agent in the oily vehicle at a temperature not exceeding 70&#xb0; C.

Pharmaceutical composition based on macrolides for topical application in ophthalmology

The invention concerns a device comprising a flask ( ) with variable internal volume having a rigid neck ( ) wherein is arranged the body ( ) of a dispensing head ( ) ending in a conduit ( ) discharging the liquid and containing a microporous pad ( ) for generating a head loss regulating the liquid flow pushed therethrough into a distribution chamber ( ) communicating with said conduit. The pad is advantageously made of a material inert with respect to the liquid and combined with an antibacterial filtering element ( ) preventing outside air from entering the flask. It evenly occupies the body ( ) over the whole cross-section of the liquid passage.

Device for packaging a liquid to be dispensed drop by drop

Osteoplasty material substantially devoid of antigenic proteins, wherein the material contains a natural bone structure in which non-denatured type I collagen is integrated, is prepared by selective extraction of bone tissue of human or animal origin. The selective extractant is an aqueous solution of 2-10 molar urea, and the extraction step is conducted at preferably 10.degree.-30.degree. C.

Method of manufacture of a material for osteoplasty from a natural bone

Growing community of inventors

Ceyrat, France

Jacques Luyckx